Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a biotechnology company that uses its proprietary DDX platform to develop gene therapies for diseases with high unmet clinical needs, such as Non-Muscle Invasive Bladder Cancer (NMIBC). With promising results from its pivotal LEGEND Phase 2 trial and a strong cash reserve of $266.3M, enGene is well-positioned to move towards BLA submission in 4Q26 and potential FDA approval. However, key questions regarding durability, competitive efficacy and durability data, and NCCN guideline inclusion remain, along with risks such as clinical, regulatory, and financial challenges, which could impact the company's share price and future success.

Bears say

enGene Therapeutics is developing a gene therapy product, detalimogene, for Non-Muscle Invasive Bladder Cancer (NMIBC) patients. While initial data showed potential for this product, recent updates have shown a decline in response rates and durability compared to other competitors in the market. Additionally, the company's financials show an increase in operating expenses and a decrease in cash, causing concerns about their ability to effectively bring this product to market. Questions remain about the efficacy and potential of detalimogene, as well as the company's regulatory strategy and financial stability, leading to a negative outlook on their stock.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.